The stock of Kadmon Holdings Inc (NYSE:KDMN) hit a new 52-week low and has $6.42 target or 12.00% below today’s $7.29 share price. The 6 months bearish chart indicates high risk for the $316.19 million company. The 1-year low was reported on Sep, 30 by Barchart.com. If the $6.42 price target is reached, the company will be worth $37.94M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 52,433 shares traded hands. Kadmon Holdings Inc (NYSE:KDMN) has risen 6.00% since August 31, 2016 and is uptrending. It has underperformed by 4.42% the S&P500.
Kadmon Holdings Inc (NYSE:KDMN) Ratings Coverage
Out of 4 analysts covering Kadmon Holdings (NYSE:KDMN), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Kadmon Holdings has been the topic of 4 analyst reports since August 22, 2016 according to StockzIntelligence Inc. The stock of Kadmon Holdings Inc (NYSE:KDMN) has “Buy” rating given on Monday, August 22 by H.C. Wainwright. On Monday, August 22 the stock rating was initiated by JMP Securities with “Outperform”. On Monday, August 22 the stock rating was initiated by Jefferies with “Buy”. The stock of Kadmon Holdings Inc (NYSE:KDMN) has “Neutral” rating given on Monday, August 22 by Citigroup.
According to Zacks Investment Research, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York.”
More notable recent Kadmon Holdings Inc (NYSE:KDMN) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on July 26, 2016, also Businesswire.com with their article: “Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in …” published on September 21, 2016, Marketwatch.com published: “Sam Waksal’s Kadmon Holdings prices IPO” on July 26, 2016. More interesting news about Kadmon Holdings Inc (NYSE:KDMN) were released by: Businesswire.com and their article: “Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma” published on August 29, 2016 as well as Cnbc.com‘s news article titled: “Sam Waksal’s Kadmon Holdings shares open below offering price in debut” with publication date: July 27, 2016.
KDMN Company Profile
Kadmon Holdings, Inc., formerly Kadmon Holdings, LLC, is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of small molecules and biologics. The Firm is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. The Company’s product candidates include KD025, Tesevatinib in Oncology, Tesevatinib in polycystic kidney disease (PKD) and KD034. It also offers tablets and capsules, such as Ribasphere RibaPak, Ribasphere tablets, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.